PCACP significantly inhibited HCC cell proliferation and tumor growth by targeting mTOR (mechanistic target of rapamycin), PAK4 (p21-Activated kinase 4), RHOC (Rho-related GTP-binding protein) and epithelial mesenchymal transition (EMT) pathways both in vitro and in vivo [87]. The gene discussed is PAK4; the disease is neoplasm.